Anavex Life Sciences Corp (AVXL)

[falconer66a]

Researchers haven’t found blarcamesine cancers.

SIGMAR1 protects healthy gene expression through Chromatin Remodeling
(pre-transcription

That should be cancer protective by reducing the number of errors in transcription which are thought to be a source of cancer mutations.

Exactly.

Beyond blarcamesine’s potential of reducing mutogenic transcription errors (which can cause cancer) are the drug’s well-characterized abilities to modulate, restore, or promote normal cell-keeping processes, such as autophagy and proper protein folding.

Cancers are not common in fourteen-year-olds. Rather common for people in their sixties. Cell-keeping, homeostasis, is fully functional in earlier years, but with age cells fail to adequately deal with metabolic wastes, some of which are carcinogenic. Autophagy (chemical processing and elimination of cellular wastes) often becomes compromised with age, as does the cell’s ability to synthesize properly-folded enzymes, thereby compromising all sorts of enzyme-controlled cell processes, including the suppression of mutations or untoward gene expression events.

If blarcamesine is carcinogenic, it hasn’t been yet discovered in any of the organisms it’s been tested in. For aging studies, the roundworm Caenorhabditis elegans is a recognized model organism. To date, no reports of any aging problems with blarcamesine with C. elegans; or any other species. Is it merely researcher incompetence; or an actual trait of blarcamesine?